A number of studies in animal models and humans have shown that both humoral and cell-mediated immune responses play an important role in the control of viral infection and tumor development. In most cases, vaccination with non-vectorized peptides or proteins induces low antibody responses and fails to elicit speci®c cytotoxic T lymphocytes (CTL). In order to make vaccination more ef®cient, we chemically coupled the non-toxic B subunit of Shiga toxin (STxB) to a full-size antigenic model protein, ovalbumin (OVA), yielding STxB-OVA. We found that STxB-OVA delivers OVA-derived peptides into both the MHC class I-and II-restricted presentation pathways in mouse dendritic cells. Accordingly, the study of STxB traf®cking in these cells revealed that, after internalization, a fraction of STxB followed the retrograde transport pathway to the endoplasmic reticulum, while another fraction was targeted to late endosomes/lysosomes. Vaccination of mice with STxB-OVA primed a speci®c anti-OVA CTL response without the use of adjuvants. Splenocytes and, particularly, CD4 + T cells from mice immunized with STxB-OVA also produced higher amounts of the T h 1 cytokine IFN-g and IgG2a-type antibodies than mice immunized with non-vectorized ovalbumin. In conclusion, this study identi®es a unique non-live vaccine delivery system for polyepitopic antigens that elicits antigen-speci®c CTL, a humoral immune response and a T h 1-type polarization without the use of adjuvant.
Introduction
In recent years, various strategies have been used for the development of vaccines against viruses and tumors. In contrast to current anti-bacterial vaccines whose ef®cacy mainly depends on their ability to elicit protective antibodies, vaccines designed to induce anti-tumor or anti-viral immunity must also boost the cell-mediated immune response, especially speci®c cytolytic T lymphocytes (CTL) (1±2). Since CD8 + and CD4 + T lymphocytes recognize peptides associated with MHC class I or II molecules respectively, peptide reagents were ®rst used as immunogens for these vaccines.
Synthetic peptide vaccines have led to tumor protection or virus clearance in murine models (3, 4) . However, in most cases, peptides failed to elicit ef®cient immune and clinical responses (5) . Furthermore, in some instances, peptides have been found to induce speci®c T lymphocyte tolerance (6±7). Various groups have claimed that an improvement of the immunogenicity of peptides was observed when they were associated with adjuvants, coupled to vectors, pulsed to dendritic cells or engineered to enhance their af®nity for MHC molecules. Nevertheless, human trials conducted with peptides in these different formulations gave rise to modest clinical responses (8±10). When CTL were elicited after highdose peptide vaccination, multiple in vitro immunizations were required to detect these CTL which often presented a low avidity (11±14).
The relative failure of peptide-based vaccines is likely related to recently discovered escape mechanisms developed by viruses and tumors.
Indeed, a mono-epitopic CTL response against retroviruses has frequently led to the emergence of virus escape mutants and subsequent disease progression (15±16). Cumulative evidence also suggests that tumor cells could escape immune attacks induced by peptides by means of partial or total loss of expression of tumor antigen and MHC class I molecules (17) .
The use of peptide vaccines also raises a number of concerns, as immunodominant peptides have not been identi®ed for most antigenic proteins. When a candidate immunodominant epitope has been selected, it varies from one individual to another, which may explain why, even in subjects with the same HLA class I haplotype, the detectable CTL response to a given pathogen is not necessarily identical (18) . The use of peptides is also restricted to patients with a particular type of HLA and is not applicable to large outbred populations.
All these considerations argue in favor of the use of full-size proteins as model antigens to overcome many of the disadvantages of peptide vaccines. Unfortunately, administration of soluble proteins alone generally does not induce CTL responses, presumably because the antigen is not introduced into the MHC class I antigen presentation pathway. Its ef®ciency to elicit antibody is also often poor, requiring the use of adjuvants (19) .
Attenuated recombinant live vectors, such as virus or bacteria, and naked plasmid DNA encoding large antigenic proteins have been shown to induce humoral and cytotoxic T cell responses (20±22). However, a number of safety issues have not been conclusively resolved (23) . For example, reversion of attenuated live vectors to virulent strains by genetic recombination cannot be excluded. Furthermore, even attenuated viral or bacterial strains are associated with health risks for immunode®cient recipients. With respect to DNA vaccines, the consequences of stable integration of exogenous DNA into the host genome have not been clearly established. Synthetic vectors or adjuvants with the ability to increase immunogenicity of full-size proteins are therefore eagerly awaited.
Shiga toxin from Shigella dysenteriae is composed of an A subunit which mediates toxicity and a B subunit (STxB), a nontoxic homopentameric protein responsible for toxin binding and internalization into target cells by interacting with the glycolipid Gb 3 . In a previous study, we showed that STxB ef®ciently targeted peptides into the MHC class I pathway and induced peptide-speci®c CTL in mice (24, 25) . In the present work, we show that STxB, coupled to full-size protein, mediates the delivery and presentation of peptides derived from an antigenic model protein by both MHC class I and II molecules. In addition, STxB elicits a humoral and cytotoxic T cell response associated with a T h 1-dominant polarization in mice.
Methods
Mice Female C57BL/6 (H-2 b ) and BALB/c mice from Iffa Credo (L'Arbresle, France) at were used 6±8 weeks of age.
Recombinant proteins and peptides
To allow for chemical coupling of antigenic peptides or proteins to a de®ned acceptor site in STxB, a Cys was added to the C-terminus of the wild-type protein, yielding STxB-Cys. The recombinant mutant STxB-Cys protein was produced as previously described (25) . Endotoxin concentrations determined by the Limulus assay test (Biowhittaker, Walkersville, MD) were <0.5 EU/ml.
Puri®ed chicken ovalbumin (OVA) (grade V) was obtained from Sigma (St Quentin Fallavier, France).
OVA was linked to STxB-Cys by chemical coupling. Brie¯y, OVA was ®rst activated via amino groups on lysine side chains using the hetero-bifunctional cross-linker MBS (Pierce, Rockford, IL). Activated OVA was then reacted with STxBCys, and the reaction product was puri®ed by gel ®ltration and immunoaf®nity chromatography.
The synthetic OVA-derived peptides OVA 257±264 (SL8) and OVA 323±339 encompassing the 257±264 and 323±339 residues of OVA respectively were obtained from Altergen (Schiltiggheim, France) and stored in PBS.
Cell lines
The D1 dendritic cell line, obtained from P. RicciardiCastagnoli, was cultured in IMDM (Sigma) supplemented with 10% heat-inactivated FCS, 2 mM glutamine (Sigma), 5 mM sodium pyruvate and 50 mM 2-mercaptoethanol with 30% conditioned medium from granulocyte macrophage colony stimulating factor-producing NIH-3T3 (R1 medium), as previously described (26) . The mouse thymoma cell line EL4 (H-2 b ) was kindly provided by K. Rock (University of Massachusetts Medical School, Worcester, MA), and maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM glutamine (Sigma), 5 mM sodium pyruvate, 50 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 mg/ml streptomycin. B3Z is a CD8 + T cell hybridoma speci®c for the OVA 257±264 peptide in the context of K b , which carries a LacZ construct driven by NF-AT elements from the IL-2 promotor. It was a generous gift from N. Shastri (University of California, Berkeley, CA). BO97.10.5, a CD4 + T cell hybridoma speci®c for the OVA 323±339 in the context of I-A b , was provided by L. Adorini (Roche Milano Ricerche, Italy).
Bone marrow-derived dendritic cells were prepared as previously described (25) Inhibition of Gb 3 expression D1 dendritic cells were cultured for 6 days with 5 mM 1-phenyl-2-hexa-decanoylamino-3-morpholino-1-propanol (PPMP; Calbiochem, La Jolla, CA). Gb 3 and K b expression were monitored by cytometry. Activation of the hybridoma cells was determined by IL-2 production in the supernatants harvested 18 h after co-culture and measured by a commercial ELISA (PharMingen, San Diego, CA).
Antigen-presentation assay
In some experiments, lactacystin (Biomol, Plymouth Meeting, PA) was used for inhibition studies.
Cytotoxicity assay
Cytotoxicity was assessed on 51 Cr-labeled target cells, as previously described (27) .
Serological analysis
Mice were immunized i.p. 3 times at 2-week intervals with the various immunogens. Blood was collected 1 week after the last immunization by retro-orbital puncture using heparinized glass pipettes.
Anti-OVA IgG1 and IgG2a antibodies were measured by ELISA. Brie¯y, 96-well break-away,¯at-bottomed microtiter plates (Nunc, Roskilde, Denmark) were coated with 100 ml of OVA (50 mg/ml) diluted in carbonate buffer (0.1 M Na 2 CO 3 / NaHCO 3 , pH 9.6) overnight at 4°C. The plates were then saturated with 200 ml of PBS/1% BSA for 1 h at room temperature. After washes with PBS/0.05% Tween 20 (Merck, Schuchardt, Germany), 100 ml of diluted mouse serum was added and incubated for 2 h at 37°C. After washes, the plates were incubated with 100 ml of alkaline phosphatase-labeled goat anti-mouse IgG1 or IgG2a antibodies (Southern Biotechnologies, Birmingham, AL) for 2 h at room temperature. The wells were then rinsed 3 times and 50 ml of phosphatase substrate (Sigma) was added. The absorbance was read at a wavelength of 405 nm.
Cytokine assay
Splenocytes, previously primed in vivo, were plated on 96-well plates at 8 Q 10 5 cells/well with culture medium alone or with various concentrations of OVA. Culture supernatants were collected 48 h later, and IFN-g and IL-4 were measured by ELISA using commercial kits (PharMingen).
Immuno¯uorescence study
Immuno¯uorescence was performed as previously described (28) . Brie¯y, Cy3-labeled STxB was bound to D1 cells on ice, which were then incubated for 45 min at 37°C. The cells were ®xed with 3% paraformaldehyde, quenched with ammonium chloride, permeabilized and stained using the CTR433 mAb recognizing a medial-Golgi marker (gift of Michel Bornens) or an anti-Lamp-1 antibody (PharMingen).
STxB degradation experiment
To measure the proteolytic degradation of STxB in D1 cells, iodinated STxB (5000 c.p.m./ng) was bound to D1 cells on ice.
These cells were then shifted to 37°C and the amount of TCAsoluble material in the culture medium was determined as a percentage of total cell-associated radioactivity, at the indicated times.
Glycosylation experiment
The glycosylation of the STxB variant STxB-Glyc-KDEL was performed as previously described (28) . In brief, 50 nM recombinant iodinated STxB carrying an N-glycosylation site was incubated with D1 cells for 45 min on ice (time 0). After washing, cells were incubated at 37°C for various lengths of time. At the end of each incubation period, cells were solubilized in sample buffer and lysates were analyzed on 10±20% SDS±PAGE gradient gels, followed by autoradiography.
Results

Receptor-dependent delivery of exogenous whole protein into the MHC class I and II pathways via STxB
Our previous data showed that peptide-fused STxB allowed MHC class I-restricted presentation of exogenous peptides (25) . In this study, we assessed the delivery of peptides derived from full-size protein into the MHC class I and II pathways, using STxB as a vector.
D1 dendritic cells (H-2 b ), sensitized with full-size OVA chemically coupled to STxB (STxB-OVA), were able to present the immunodominant OVA-derived SL8 peptide to B3Z, an anti-SL8-speci®c CD8 ± T cell hybridoma (Fig. 1A) . To control the speci®city of T cell activation, we demonstrated that an irrelevant anti-Cw3 T cell hybridoma was not activated under the same conditions (data not shown). As low as 5 nM STxB-OVA was suf®cient to sensitize the D1 cell line for SL8 presentation (Fig. 1A) . In contrast, dendritic cells incubated with as much as 500 nM of non-vectorized OVA protein failed to allow presentation of the SL8 peptide (Fig. 1A and data not shown).
STxB could also target the SL8 peptide derived from OVA in the MHC class I-restricted presentation pathway in bone marrow-derived dendritic cells (Fig 1B) .
Since STxB speci®cally binds to the glycosphingolipid globotriaosyl ceramide, Gb 3 (CD77), we tested whether this receptor was involved in STxB-dependent MHC class I-restricted presentation.
When dendritic D1 cells were cultured for 6 days with PPMP, an inhibitor of Gb 3 synthesis, marked down-regulation of Gb 3 expression at the plasma membrane was observed, while the expression of K b class I molecules at the plasma membrane was not changed [(25) and data not shown]. PPMP-treated and STxB-OVA-sensitized D1 cells lost the capacity to present the SL8 peptide, whereas exogenous synthetic SL8 peptides incubated with PPMP-treated cells activated the speci®c T cell hybridoma (Fig. 1C) The role of Gb 3 is also supported by the inef®ciency of STxB to deliver exogenous antigen into the MHC class I pathway of Gb 3 ± cells such as T lymphocytes and some epithelial or tumor cells (data not shown).
Since CD4 + T cell responses play a critical role in the initiation of a humoral immune response, and the priming and The B subunit of Shiga toxin: an ef®cient non-live vector for vaccine 1163 differentiation of CD8 + T cells (29) , we also examined the ability of STxB-OVA to target peptides onto MHC class II molecules. When D1 cells were pulsed with soluble OVA or STxB-OVA, they presented the immunodominant OVA 323±339 CD4 peptide to a speci®c I-A b T cell hybridoma (Fig. 2) . However, compared to soluble OVA, STxB-dependent MHC class II-restricted presentation was at least 50-fold more ef®cient ( Fig. 2A and B) .
Similarly to antigen delivery into the MHC class I pathway, STxB targeting of peptides into the MHC class II pathway occurred in a receptor-dependent manner. In contrast, the presentation of peptides derived from non-vectorized soluble OVA was not inhibited by the presence of Gb 3 inhibitor (Fig 2) . When a high concentration of STxB-OVA was used in the presence of PPMP, MHC class II presentation could occur, which corresponds to¯uid phase internalization, as in the case of non-vectorized OVA (Fig. 2A) .
STxB therefore allows both MHC class I-and II-restricted presentation of peptides derived from full-size exogenous protein.
STxB-OVA processing is dependent on proteasome
The presence of lactacystin, a speci®c proteasome inhibitor, during incubation of the bone marrow-derived dendritic cells with STxB-OVA inhibited the presentation of the SL8 epitope to CD8 + T cells, whereas direct presentation of the synthetic exogenous peptide SL8 was not affected by the presence of this drug (Fig. 3) .
Analysis of the intracellular transport pathway of STxB in the D1 dendritic cells
We have previously reported that STxB has different intracellular transport itineraries in different cell types (28) . Immuno¯uorescence and biochemical studies were carried out in order to analyze STxB traf®cking in D1 cells. In a ®rst experiment, STxB was covalently linked to a¯uorescent probe (Cy3) and internalized for 45 min at 37°C into D1 cells, after binding to the plasma membrane. Accumulation of STxB in various cytoplasmic structures was observed (Fig. 4A) . In a double labeling immuno¯uorescence experiment, an overlap was revealed between STxB and a medial-Golgi marker (Fig. 4A) , suggesting that STxB enters the retrograde route in D1 cells. These results were con®rmed by a biochemical assay, in which glycosylation of a STxB variant (carrying an N-glycosylation site) by endoplasmic reticulum-located oligosaccharyl transferase was observed (Fig. 4C) . These results therefore show that after internalization into D1 cells, a fraction of STxB follows the retrograde transport pathway to the endoplasmic reticulum. Whether this targeting results in retrotranslocation of antigen into the cytosol (30, 31) remains to be established (see Discussion).
The¯uorescent studies also indicated that another fraction of STxB accumulated in the punctuate cytoplasmic structure that partially overlapped with markers of late endosomes/ lysosomes (Fig. 4B) . To directly test whether STxB could be degraded in D1 lysosomes, we monitored the appearance of TCA-soluble counts in the external medium. We observed that (10 5 ) (B) were pulsed for 5 h with full-size OVA or STxB-coupled OVA (STxB-OVA). After washing, the cells were co-cultured with the speci®c anti-SL8 B3Z hybridoma (2 Q 10 5 ) carrying a LacZ construct driven by NF-AT elements of the IL-2 promotor. SL8 is an immunodominant K b -restricted OVA-derived peptide. A colorimetric assay with ONPG as substrate was used to detect bgalactosidase activity in B3Z lysates, re¯ecting T cell hybridoma activation. (C) D1 dendritic cells were cultured for 6 days with (right) or without (left) 5 mM of PPMP, an inhibitor of glycolipid synthesis. The cells were then pulsed for 5 h with STxB-OVA (100 nM) or the immunodominant OVA-derived SL8 peptide (50 nM). After washing, the cells were co-cultured with the speci®c anti-SL8 B3Z hybridoma. Activation of the hybridoma was revealed as described in (A).
up to 14% of cell-associated STxB was degraded after 16 h (Fig. 4D) . These results are consistent with partial targeting of STxB into the endosomal/lysosomal pathway, in which peptides resulting from proteolytic processing could associate with MHC class II molecules.
STxB-OVA primes a speci®c cytotoxic T cell response
The ability of STxB to target full-size exogenous proteins in both MHC class I-and II-restricted presentation pathways led us to test whether this special feature was associated with an increased immunogenicity of proteins coupled to this vector. C57BL/6 mice were immunized on days 0 and 21 with STxB-OVA or non-vectorized OVA. On day 28, CTL activity was determined after a secondary in vitro stimulation with the immunodominant OVA-derived peptide, SL8.
As shown in Fig. 5 , spleen cells from mice immunized with STxB-OVA (1 nmol) ef®ciently lysed EL4 target cells loaded with the SL8 peptide, whereas no cytotoxicity was observed against EL4 alone. In contrast, no cytotoxic activity could be demonstrated when mice were immunized with soluble OVA alone (Fig. 5) .
As a control we showed that STxB alone did not induce anti-SL8 CTL (data not shown).
When mice were immunized with lower doses of STxB-OVA, the induction of CTL was weaker (data not shown).
STxB polarizes a T h 1-dominant immune response
Spleen cells from immunized mice were also tested in vitro for their capacity to produce cytokines in response to various doses of soluble OVA.
Splenocytes of mice vaccinated with STxB-OVA secreted signi®cantly more IFN-g in response to OVA than splenocytes of mice immunized with OVA alone or OVA associated with adjuvants (Fig. 6) . Depletion of CD4 + T cells suppressed IFN-g secretion, con®rming that the observed T h 1 response was mainly mediated by CD4 + T cells (data not shown).
We did not detect any IL-4 production by these splenocytes after vaccination with STxB-OVA or soluble OVA, although 3 . STxB-OVA processing is lactacystin sensitive. Bone marrowderived dendritic cells were preincubated or not for 1 h with lactacystin (50 mM) and then pulsed for 5 h with STxB-OVA (125 nM) or SL8 peptides (100 nM). After washing, the cells were co-cultured with the anti-SL8 B3Z hybridoma. Activation of the hybridoma was revealed as described in Fig 1. The B subunit of Shiga toxin: an ef®cient non-live vector for vaccine 1165 Downloaded from https://academic.oup.com/intimm/article-abstract/15/10/1161/665965 by guest on 24 December 2018 they secrete IL-4 after non-speci®c mitogenic stimulation (data not shown).
To assess the in vivo relevance of these results, we analyzed the antibody isotype pro®les in serum of mice immunized with STxB-OVA, as a high IgG2a:IgG1 antibody ratio has been correlated with T h 1 polarization of the immune response (32) . Mice from two different genetic backgrounds (BALB/c and C57BL/6) were immunized 3 times at 2-week intervals with STxB-OVA, OVA alone or OVA successively mixed with complete (CFA) and incomplete Freund's (IFA) adjuvants. Sera were obtained 10 days after the last immunization. Mice primed with OVA emulsi®ed in CFA and boosted with IFAassociated antigen, followed by a third immunization with antigen alone, showed high levels of anti-OVA IgG1 antibodies, whereas mice immunized with STxB-OVA or soluble OVA alone produced lower levels of these antibodies (Fig. 7A  and B) . In contrast, anti-OVA IgG2a antibodies were higher in STxB-OVA-immunized mice than in those vaccinated with OVA alone or mixed with adjuvants ( Fig. 7C and D) . These results therefore support the T h 1-dominant polarization induced by STxB.
Interestingly, STxB did not simply act as an adjuvant, like some other protein toxins, but rather exerted its activity as a vector, as no increase in IgG2a anti-OVA titers was observed when STxB and OVA were injected into mice as a simple mixture, without being physically linked (data not shown). 
Discussion
In the present study, we have shown that STxB induces both MHC class I-and II-restricted presentation of peptides derived from STxB-coupled full-size exogenous protein. We have also shown that, inside D1 dendritic cells, STxB traf®cs through two pathways and its targeting to the late endosomal/ lysosomal pathway may explain its ability to target exogenous protein into the MHC class II pathway.
The mechanisms underlying STxB-mediated MHC class I-restricted antigen presentation have yet to be fully established. STxB follows the retrograde pathway in D1 cells (Fig. 4) , as demonstrated for other cell types (33) . In toxinsensitive cells, this transport pathway allows for retrotranslocation of the catalytic toxin A subunit from the lumen of the endoplasmic reticulum to the cytosol (30±31). It therefore appears possible that STxB targets exogenous protein into the cytosol via this pathway. However, it cannot be excluded that, at least in some cell types, STxB escapes to the cytosol by a membrane translocation mechanism operating at the level of endosomes or lysosomes, as suggested for other toxins (34) .
When we previously analyzed STxB traf®cking in human monocyte-derived dendritic cells, no indication for STxB targeting to the retrograde route could be obtained (28) . Further work is required to establish at what level STxBvectorized antigenic peptides and proteins cross the endomembranes to reach the cytosol.
Vaccination of mice with STxB-coupled full-size protein enhanced both the cell-mediated and humoral immune responses against this antigen. In mice, STxB primed CTL without the use of adjuvant (Fig. 5) , which con®rms and extends our previous results on CTL induction using peptidecoupled STxB (25) .
The improvement of strategies to prime CTL represents a major goal of anti-tumor and anti-viral vaccines for various reasons. In mice, a correlation has generally been found between the ability to elicit anti-tumor CTL and clinical responses (5) . In immunotherapy protocols based on the use of ex vivo antigen-pulsed dendritic cells, the detection of T cell immunity against a de®ned antigen after vaccination coincides with clinical responses (35±36). Similarly, CD8 + T cells mediate immunity to a broad range of viral, intracellular bacteria and protozoal pathogens (37) .
Other synthetic vectors, such as pseudomonas exotoxin or Tat, ef®ciently introduce exogenous peptides into the MHC class I pathway, but failed to elicit CTL in mice (38±40). The fact that STxB, like other toxins, preferentially targets dendritic cells (25, 41) , the most powerful professional antigen-presenting cells (APC), may be a clue to explain its ef®ciency at inducing CTL. However, a recent study has shown that the delivery of antigen to dendritic cells without induction of their maturation failed to produce sustained antigen-speci®c immunity (42) . Some non-live vectors that are ef®cient in triggering T cell immunity, such as the outer membrane protein A from Klebsiella pneumoniae (OmpA) or some heat shock proteins, target professional APC and induce their maturation (43±44). STxB does not appear to directly favor the maturation of DC, but it has been shown that STxB stimulates the production of tumor necrosis factor-a, a cytokine which acts as a maturation factor (45). In contrast, the use of vectors that lead to rapid dissemination of antigens through the body and internalization into nonprofessional APC may lead to tolerance.
Splenocytes, and particularly CD4 + T cells, from mice immunized with STxB-OVA also produced higher amounts of the T h 1 cytokine IFN-g than mice immunized with nonvectorized OVA (Fig. 6) . Since T h 1 responses play an important role in protection against intracellular pathogens and tumors, the induction of such T h 1 polarization is highly desirable for vaccines designed to target these diseases (46, 47) .
Although cytotoxic CD8 + T cells are considered to be the principal effectors of most anti-tumor and anti-viral immune responses, CD4 + T cells provide crucial helper functions required to prime and sustain the CD8 response, and activate NK and B cells. Recent studies have indicated that the licensing signal required for ef®cient priming of CTL and provided by CD4 + T cells to dendritic cells is mediated via CD154 signaling on CD40 of host APC (48±50). Ef®cient CTL induction also requires that the formation of peptide±class II complexes which are recognized by CD4 + T cells occurs as a result of intracellular processing and not following direct loading of free peptide onto class II molecule (51) . The use of polypeptides or full-size proteins for the design of vaccines that ef®ciently induce cell-mediated responses therefore appears preferable over CD8 peptides alone or mixtures of CD4 and CD8 peptides.
Finally, immunization of mice with STxB coupled to OVA enhanced the production of IgG2a anti-OVA antibodies when compared to vaccination with OVA alone or OVA associated with CFA and IFA (Fig. 6C and D) . IgG2a production might be secondary to STxB-induced IFN-g secretion, a cytokine that favors the switch from IgM to IgG2a (32) . In this context, although methods to induce antibody production are less actively pursued in the development of anti-tumor or anti-viral vaccines, convincing data nevertheless demonstrated that antibodies may participate in the host defense in these clinical situations. For example, tumor protection induced after vaccination with idiotype-pulsed dendritic cells was associated with the induction of high titers of anti-Id antibodies of the IgG2a subclass (52) . Similarly, a number of studies in animal and human models have shown a protective role of antibodies against acute infection with HIV-1 and simian HIV strains (53±55). It is noteworthy that protective antibodies are also elicited in the course of natural HIV infection (56) .
When live vectors such as recombinant viruses are used for vaccine development, the immune response to virus proteins is a signi®cant limitation to successful immunization in animals and humans. Even when viruses whose natural hosts are nonmammalian are used, such as avian poxvirus, a remaining problem is that immunity to antigenically complex vaccine vectors may diminish the reactivity to the selected antigen via the poorly understood mechanism of immunodominance (57) . Immunogenicity concerns appear less relevant in the case of synthetic vectors, as it has been shown that preimmunization of mice with these non-live vectors did not compromise the subsequent immune response (27, 58, 59) .
Conclusions
There is a great need for immunological adjuvants or vectors that are capable of stimulating both antibody and CTL responses to vaccine antigens. STxB is a powerful vaccine delivery system for polyepitopic antigens that can elicit antigen-speci®c CTL, humoral immune responses and T h 1 polarization without the use of adjuvant. 
